J&J hands back rights to Addex’s Phase II asset

17 April 2025

Switzerland-based Addex Therapeutics (SIX/Nasdaq: ADXN), a biopharma developing a portfolio of novel small molecule allosteric modulators for neurological disorders, has announced an update on its Phase II asset, ADX71149.

Following the previously-announced termination of development of the drug, also known as JNJ-40411813, in epilepsy, Addex’s partner Janssen Pharmaceuticals - now J&J Innovative Medicine - has returned all development and commercialization rights to the candidate and the partnership between the two companies has come to an end.

Tim Dyer, chief executive of Addex, said: “ADX71149 is a high-quality asset which has completed three Phase II studies so we are excited to regain control of its development from our partner with its high-quality data package and significant material.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK